Nucleai is leading the spatial biology revolution in precision medicine.
Employees: 11-50
Founded date: 2017
Investors 3
Mentions in press and media 6
| Date | Title | Description |
| 10.04.2019 | This Israeli startup leverages AI to help pathologists handle their workload | After witnessing his father go through this, he met with pathologists to learn about their work and the importance of pattern recognition. Veidman also realized that there’s a shortage of pathologists and that they’re human beings who make ... |
| 02.07.2018 | Precipio partners with AI-healthcare startup Nucleai to develop artificial intelligence-powered hemepath solution | Precipio, a cancer diagnostics reference laboratory, is partnering with Israel-based artificial intelligence pathology platform startup Nucleai, to develop artificial intelligence-powered hemepath solution. Nucleai specializes in applying M... |
| 06.04.2018 | Despite hype, AI did not exactly rake in investment dollars in Q1 | Another new segment broke down deals by specialty. The agnostic category is a little puzzling in this context — even if it is simply administrative software that could be used in any specialty the data would be more worthwhile if it just fo... |
| 06.03.2018 | Vertex Ventures Israel co-leads $5m seed round in cancer detection startup Nucleai | Premium Vertex Ventures Israel and Grove Ventures Capital Ltd have co-led a $5-million seed round in Nucleai Ltd, a Tel Aviv-based startup that uses artificial intelligence and machine learning algorithms to detect cancer and other diseases... |
| - | This Israeli startup leverages AI to help pathologists handle their workload | Avi Veidman spent a good portion of his career in the Israeli intelligence forces, where he worked on big data and AI. After he retired, he knew he wanted to build a startup. While he was interested in healthcare and agriculture, he didn’t ... |
| - | Despite hype, AI did not exactly rake in investment dollars in Q1 | A new digital health investment report from StartUp Health found that investors poured $2.8 billion into 191 deals. The report this year reflects a rethink of how the organization presents the health tech investment landscape. One noticeabl... |